IMMUTEP

Immutep's first-in-class LAG-3 agonist antibody IMP761 demonstrated 80% inhibition of T cell infiltration at 0.9 mg/kg dose with no treatment-related adverse events in healthy participants.

Bristol-Myers Squibb's Opdualag, the first FDA-approved LAG-3 inhibitor combination, generated $58 million in second-quarter sales following its March approval for metastatic melanoma.

• The LAG-3 next-generation immunotherapies market is projected to grow from $463.6 million in 2024 to $5.5 billion by 2035, driven by increasing solid tumor cases and expanding treatment options. • Bristol Myers Squibb's Opdualag (nivolumab/relatlimab) has established a foundation for LAG-3 therapies, with promising candidates from Merck, Regeneron, and Immutep advancing through clinical trials. • Biomarker-driven precision medicine and strategic regulatory support are accelerating development of novel LAG-3 therapies, including monoclonal antibodies, bispecific antibodies, and soluble LAG-3 molecules.

Immutep's EFTISARC-NEO Phase II trial, evaluating eftilagimod alpha with radiotherapy and Keytruda, has completed enrollment of 40 patients with resectable soft tissue sarcoma.

The INSIGHT-003 trial, evaluating eftilagimod alpha (efti) with pembrolizumab and chemotherapy, has completed enrollment with approximately 50 patients.

Immutep's IMP-761, a LAG-3 agonist, demonstrates a favorable safety profile in Phase I trials, potentially addressing autoimmune diseases like rheumatoid arthritis.

Immutep has commenced its Phase III TACTI-004 trial to evaluate eftilagimod alfa in combination with pembrolizumab and chemotherapy for first-line metastatic non-small cell lung cancer.

Immutep's pivotal TACTI-004 trial of eftilagimod alfa (efti) in first-line non-small cell lung cancer (1L NSCLC) has received regulatory approval, marking the company's transition to Phase III.

Immutep's eftilagimod alpha, when combined with Merck's Keytruda, demonstrates improved survival rates in first-line lung cancer treatment, suggesting a potential new therapeutic approach.

Immutep's Phase II clinical trial for soft tissue sarcoma treatment shows positive results, marking a potential advancement in managing this cancer.